Country GuideMedical AccessPublic Esketamine + Trials Only

Country Access Report

Medical Access and Reimbursement in Israel

Israel has documented public/HMO access to intranasal esketamine under criteria, while racemic ketamine is off-label and payer-specific. Classical psychedelics remain controlled, investigational or exceptional-access therapies rather than routine reimbursed medicines.

Access Level
Public Esketamine + Trials Only
Compounds Covered
10
Active Trials
5

Access by Compound

Compound-specific notes summarise what is realistically available through approved medical use, clinical research, exceptional access, or private care where the country report has verifiable information.

Compound Access

Psilocybin

Research only

Psilocybin should be framed as research-stage in Israel. Hebrew University and Hadassah-linked work is scientifically visible, but no routine authorised medical access or reimbursement pathway was identified. # #

Compound Access

MDMA

Trials and historic compassionate use only

MDMA is active in Israeli PTSD research, including the Sheba-sponsored post-7-October trial. The 2019 MAPS-reported compassionate-use decision is historically important but should not be described as current open access. # # #

Compound Access

Esketamine

Public/HMO pathway under criteria

Intranasal esketamine is the clearest documented access route. Ministry of Health materials, HMO eligibility pages and Israeli real-world data support supervised treatment-resistant depression use inside the health system. # # # #

Compound Access

Ketamine

Off-label; payer-specific

Racemic ketamine is clinically used and studied in Israel, but psychiatric treatment is better described as off-label and institution- or payer-specific. Regulation 29 is relevant for off-label and unregistered-use handling; it is not proof of routine reimbursement. # #

Compound Access

DMT

Controlled; no routine medical access

DMT should be treated as controlled with no routine medical access route identified. Any lawful use would need to move through research, import or exceptional-use permissions. # #

Compound Access

5-MeO-DMT

No routine medical access

No authorised or routinely reimbursed 5-MeO-DMT treatment pathway was identified in Israel. Public evidence supports research controls rather than patient access. # #

Compound Access

Ibogaine

No routine medical access

No routine authorised ibogaine treatment or reimbursement pathway was identified in Israel. Any claimed use should be verified against Ministry of Health permissions and controlled-drug rules. # #

Compound Access

Ayahuasca

No authorised medical access

No authorised ayahuasca medical pathway or reimbursement route was identified. DMT-containing use should be treated as controlled unless covered by a specific research or medical permission. # #

Compound Access

Mescaline

Controlled; no routine medical access

Mescaline should be treated as a controlled classical psychedelic in Israel. No routine medical access or reimbursement pathway was identified. #

Compound Access

2C-X

No routine medical access

No authorised or reimbursed medical access pathway was identified for 2C-family compounds in Israel. Claims of clinical access would need direct regulator or trial confirmation. # #

Sources and Verification

Last updated 13 May 2026. Source links are drawn from citation annotations in the medical access and reimbursement guide.

  1. 1Hebrew University psilocybin paper
  2. 2Israel controlled substances import service
  3. 3Israel Dangerous Drugs Ordinance
  4. 4Israel Ministry of Health depression care page
  5. 5Israel Regulation 29 district pharmacy approval
  6. 6Israel Spravato patient safety card
  7. 7Israeli real-world esketamine paper
  8. 8Maccabi Spravato eligibility page
  9. 9MAPS Israel MDMA compassionate use notice
  10. 10Shalvata ketamine route comparison record
  11. 11Sheba MDMA PTSD trial record